Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
STUDY MK-3475-045 PEMBROLIZUMAB INTRAVENOUS SOLUTION (HCPCS J3406) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 10, 2026 , from http://ppman.hank.ai/transparency/procedure/J3406/by-state?code_type=HCPCS
“STUDY MK-3475-045 PEMBROLIZUMAB INTRAVENOUS SOLUTION (HCPCS J3406) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/J3406/by-state?code_type=HCPCS. Accessed
November 10, 2026 .
“STUDY MK-3475-045 PEMBROLIZUMAB INTRAVENOUS SOLUTION (HCPCS J3406) by State,” HANK Price Transparency ,
accessed November 10, 2026 ,
http://ppman.hank.ai/transparency/procedure/J3406/by-state?code_type=HCPCS.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
HCPCS · across United States
J3406 — Study Mk-3475-045 Pembrolizumab Intravenous Solution
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$0
National median
$0 – $735,534
IQR (p25 – p75)
5
hospitals filing
2
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for J3406 (HCPCS), with interquartile range
State Median p25 p75
NC $0 $0 $0
ME $735,534 $735,534 $741,051